Market capitalization | CHF122.75m |
Enterprise Value | CHF160.89m |
P/E (TTM) P/E ratio | 8.71 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.31 |
P/S ratio (TTM) P/S ratio | 2.53 |
P/B ratio (TTM) P/B ratio | 89.72 |
Revenue growth (TTM) Revenue growth | 450.19% |
Revenue (TTM) Revenue | CHF48.56m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Newron Pharmaceutical:
1 Analyst has issued a forecast Newron Pharmaceutical:
Dec '24 |
+/-
%
|
||
Revenue | 49 49 |
450%
450%
|
|
Gross Profit | - - |
-
|
|
EBITDA | 25 25 |
324%
324%
|
EBIT (Operating Income) EBIT | 25 25 |
318%
318%
|
Net Profit | 15 15 |
194%
194%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
Head office | Italy |
CEO | Stefan Weber |
Founded | 2002 |
Website | www.newron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.